

DATA EXTRACTION

Study Description

Study ID



Title



First Author



Journal



Year



WG assignment



- Clinical
- Biomarker

[Clear above selection](#)

Study Design



- Case report
- Case series
- Cohort study
- Non-randomized controlled trial
- Randomized controlled trial
- other

[Clear above selection](#)

Data Collection



- Cross-sectional
- Longitudinal
- Retrospective
- Prospective

[Clear above selection](#)

Workgroup-specific quality assessment

Clinical description sufficient? 

- no (->consider exclusion)
- yes
- not relevant (biomarker focus)

[Clear above selection](#)

If not, please comment 

Are methodological details about biomarker quantification sufficient? 

- no (->consider exclusion)
- yes
- no relevant (clinical focus)

[Clear above selection](#)

If not, please comment 

Is JC-related disease sufficiently likely based on the reported data? 

- no (->consider exclusion)
- yes

[Clear above selection](#)

If not, please comment 

Recommend to exclude from data extraction 

- yes
- no

[Clear above selection](#)

If excluded, provide reason: 

- duplicate study
- not meeting eligibility criteria
- quality concern (see above)
- other reason

[Clear above selection](#)

If "other reason" selected, please provide details: 

Patient Population and PML Diagnosis

Race and Ethnicity of patients

Check all that apply



	Number of patients
Asian	
Black or African American	
White	
Hispanic or Latino	
Other	
Multiple	
Not reported	

Disease population



	Number of patients
HIV	
Hemato-onco	
Autoimmune disease	
MS-natalizumab	
Solid organ transplant	
Primary immunodeficiency	
Sarcoidosis	
HSCT	
MS-not natalizumab	
Idiopathic PML	
Other	
Total patient number	

2013 PML Diagnostic criteria



	Number of patients meeting criteria	Number of patients not meeting criteria
2013 diagnostic criteria applied by authors		
2013 diagnostic criteria applied by us		

If 2013 Diagnostic Criteria applied, PML diagnostic certainty



	Number of patients definite PML	Number of patients probable PML	Number of patients possible PML
2013 PML diagnostic criteria applied by authors			
2013 PML diagnostic criteria applied by us			

Biopsy performed



	biopsy performed	biopsy not performed
n patients		

JCV DNA in CSF (qualitative)



	detected	never detected	not tested
n patients			

JCV DNA in CSF (quantitative in positives)



	low (<200 c/ml)	high (>=200 c/ml)
n patients		

JCV DNA in CSF (n attempts to first positive CSF)



	first attempt	second attempt	more than two attempt
n patients			

If JCV DNA in CSF not detected, were details of PCR methodology provided?



Yes

No

Clear above selection

Clinical Description of PML

Clinical description provided



	yes	no
n patients		

Clinical description consistent with 2013 Diagnostic Criteria



	yes	no
n patients		

If clinical description not consistent with 2013 Diagnostic Criteria, explain:



Atypical clinical presentation



	yes	no
n patients		

If atypical clinical presentation, is it consistent with described JCV infection variants?



	n patients
Asymptomatic presentation: no neurological deficits	
GCN: subacute, progressive cerebellar ataxia	
Encephalopathy: change in mental status +/- focal neurological deficits	
Meningitis: headache, meningismus, change in mental status	

Please describe details of atypical clinical presentation




PML-IRIS

Was PML- IRIS diagnosed? 

	yes	no
n patients		

Were inflammatory features described? 

	yes	no
n patients		

If IRIS diagnosed, on what basis did the authors make determination? 

	n patients
clinical symptoms	
MRI features	
laboratory evidence of immune reconstitution	
laboratory evidence of decline in JCV DNA	
therapeutic history	
other/composite	

If inflammatory features described, what were they? 

	n patients
new or worsening clinical symptoms	
MRI features	
laboratory evidence of immune reconstitution	
laboratory evidence of decline in JCV DNA	
therapeutic history	
other/composite	

If IRIS diagnosed, please check all clinical features that apply (case reports only): 

- worsening of previous neurological deficits
 - development of new neurological deficits in patient with previous deficits
 - development of new neurological deficits in patient without previous deficits (unmasking)
 - acceleration of progression of neurological deficits
 - new onset cognitive changes
 - new onset seizures
 - other
- [Clear above selection](#)

PML Diagnostic Biomarkers

PML diagnosis based on JCV DNA PCR in CSF 

	yes	no
n patients		

If JCV DNA PCR in CSF not used, how was diagnosis established 

	n patients
brain biopsy	
MRI only without direct evidence for JCV	
CSF JCV antibody index	
alternative laboratory-based marker	

If alternative laboratory-based marker, explain: 

